CN109890388B - 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 - Google Patents

毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 Download PDF

Info

Publication number
CN109890388B
CN109890388B CN201780066073.2A CN201780066073A CN109890388B CN 109890388 B CN109890388 B CN 109890388B CN 201780066073 A CN201780066073 A CN 201780066073A CN 109890388 B CN109890388 B CN 109890388B
Authority
CN
China
Prior art keywords
disorder
compound
pharmaceutically acceptable
thieno
machr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780066073.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109890388A (zh
Inventor
C·W·林斯利
D·W·恩格尔斯
P·J·康恩
S·R·博林格
J·L·恩格尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN109890388A publication Critical patent/CN109890388A/zh
Application granted granted Critical
Publication of CN109890388B publication Critical patent/CN109890388B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780066073.2A 2016-11-07 2017-11-07 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 Active CN109890388B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662418651P 2016-11-07 2016-11-07
US62/418,651 2016-11-07
US201762542621P 2017-08-08 2017-08-08
US62/542,621 2017-08-08
PCT/US2017/060306 WO2018085803A1 (en) 2016-11-07 2017-11-07 Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Publications (2)

Publication Number Publication Date
CN109890388A CN109890388A (zh) 2019-06-14
CN109890388B true CN109890388B (zh) 2023-03-28

Family

ID=62076815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780066073.2A Active CN109890388B (zh) 2016-11-07 2017-11-07 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂

Country Status (7)

Country Link
US (1) US11008335B2 (https=)
EP (1) EP3534901B1 (https=)
JP (1) JP7098167B2 (https=)
CN (1) CN109890388B (https=)
BR (1) BR112018013882A2 (https=)
MA (1) MA46722A (https=)
WO (1) WO2018085803A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003417B1 (pt) 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
EP3544961B1 (en) 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US10961253B2 (en) 2016-11-07 2021-03-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CA3108076A1 (en) * 2018-09-04 2020-03-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892288A (zh) * 2010-02-11 2013-01-23 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002009760A2 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
PE20060526A1 (es) 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
EP1619196A1 (de) 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
ES2349416T3 (es) 2004-10-25 2011-01-03 Eli Lilly And Company Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4.
ES2259892B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
WO2007146284A2 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
US20100009934A1 (en) 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
US9056876B2 (en) 2011-09-16 2015-06-16 Vanderbilt University Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CA2859985C (en) 2011-12-21 2020-11-03 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same
US8697888B2 (en) 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9056875B2 (en) 2012-08-31 2015-06-16 Vanderbilt University Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20160200733A1 (en) * 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9981920B2 (en) 2014-06-26 2018-05-29 Rodin Therapeutics, Inc. Inhibitors of histone deacetylase
BR112018003417B1 (pt) 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
EP3544961B1 (en) 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US10961253B2 (en) 2016-11-07 2021-03-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892288A (zh) * 2010-02-11 2013-01-23 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents;Michael Bubser 等;《ACS Chemical Neuroscience》;20140728;第 5 卷(第10 期);全文 *
Synthesis and Pharmacological Evaluation of M4 Muscarinic Receptor Positive Allosteric Modulators Derived from VU10004;Tracey Huynh等;《ACS Chemical Neuroscience》;20150410;第6 卷(第 6 期);全文 *

Also Published As

Publication number Publication date
EP3534901A4 (en) 2020-04-22
US20200181166A1 (en) 2020-06-11
MA46722A (fr) 2019-09-11
JP2019537592A (ja) 2019-12-26
JP7098167B2 (ja) 2022-07-11
WO2018085803A1 (en) 2018-05-11
US11008335B2 (en) 2021-05-18
CN109890388A (zh) 2019-06-14
EP3534901B1 (en) 2022-06-22
BR112018013882A2 (pt) 2018-12-18
EP3534901A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
CN109890388B (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CN111491920B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP7038414B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7016471B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN109863139B (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
JP7099725B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP2019504901A (ja) ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター
US10342782B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN111565718A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN111788182A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11376254B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20190330226A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP2022553284A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能の阻害剤
CN111433212A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
US10189857B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M4
US12065433B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN121002031A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的吡咯并吡啶衍生物
HK40014595A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
HK40014595B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant